 Aniline Compounds
"Aniline Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the aminobenzene structure.
| Descriptor ID |
D000814
|
| MeSH Number(s) |
D02.092.146
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aniline Compounds".
Below are MeSH descriptors whose meaning is more specific than "Aniline Compounds".
This graph shows the total number of publications written about "Aniline Compounds" by people in this website by year, and whether "Aniline Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 1999 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2003 | 1 | 2 | 3 | | 2006 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 2 | 3 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 2 | 4 | | 2012 | 1 | 2 | 3 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 2 | 4 | | 2016 | 0 | 4 | 4 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 4 | 3 | 7 | | 2020 | 1 | 2 | 3 | | 2021 | 2 | 1 | 3 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 6 | 6 | | 2024 | 4 | 2 | 6 | | 2025 | 4 | 4 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Aniline Compounds" by people in Profiles.
-
Spira AI, Berz D, Jotte RM, Pachipala KK, Berger MS. Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC. Clin Lung Cancer. 2026 Jan; 27(1):75-81.
-
Venkatasubramanian R, Mahoney SA, Hutton DA, VanDongen NS, Brunt VE, Greenberg NT, Longtine AG, Brandt L, Beyer AM, Melov S, Rossman MJ, Seals DR, Clayton ZS. Cellular senescence mediates doxorubicin chemotherapy-induced vascular endothelial dysfunction: translational evidence of prevention with senolytic treatment. Am J Physiol Heart Circ Physiol. 2025 12 01; 329(6):H1672-H1683.
-
Venkatasubramanian R, Darrah MA, Mahoney SA, Hutton DA, Maurer GS, Ludwig KR, Van Dongen NS, Greenberg NT, Longtine AG, Brunt VE, Singh P, Galligan JJ, Trujillo MN, Kapahi P, Melov S, Rossman MJ, Seals DR, Clayton ZS. Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Aortic Stiffening: Role of Glycation Stress. Hypertension. 2025 Oct; 82(10):1767-1777.
-
Bamford AR, Adams JN, Kim S, Taylor LM, Tuteja N, McMillan LC, Sattari N, Chen IY, Chappel-Farley MG, Escalante Y, Lawrence AL, Meza NJ, Berisha DE, Dave A, Malhas R, Mapstone M, Mander BA, Yassa MA, Thomas EA. Salivary levels of amyloid beta reflect brain amyloid beta burden in cognitively-normal older adults. J Prev Alzheimers Dis. 2025 Aug; 12(7):100216.
-
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME. Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer. 2025 May; 203:108551.
-
Singh M, Sarhan MO, Damiba NNL, Singh AK, Villabona-Rueda A, Nino-Meza OJ, Chen X, Masias-Leon Y, Ruiz-Gonzalez CE, Ordonez AA, D'Alessio FR, Aboagye EO, Carroll LS, Jain SK. Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Nat Commun. 2025 Mar 27; 16(1):3003.
-
Vanderlip CR, Taylor L, Kim S, Harris AL, Tuteja N, Meza N, Escalante YY, McMillan L, Yassa MA, Adams JN. Amyloid-Beta Deposition in Basal Frontotemporal Cortex Is Associated with Selective Disruption of Temporal Mnemonic Discrimination. J Neurosci. 2025 03 05; 45(10).
-
Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025 05; 36(5):583-591.
-
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer. 2025 01; 199:108040.
-
Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O'Brien S, Garcia JS, Korde N, Moslehi J, Wey M, Cheung P, Sharma S, Olabode D, Chen H, Ali Syed F, Liu M, Saeh J, Andrade-Campos M, Kadia TM, Blachly JS. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024 Nov 01; 30(21):4844-4855.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|